NEW YORK (GenomeWeb) – German T-cell research tools firm Lophius Biosciences today announced an exclusive distribution agreement with BL&H for its T-Track CMV kit in South Korea.
Under the terms of the agreement, BL&H will market and sell the test to transplantation centers. The diagnostic assay combines ELISpot assay technology with T-activation technology to measure cytomegalovirus-specific cell mediated immunity in immunocompromised patients.
The kit is currently sold for research-use only, but Lophius said in a statement it expects the Korean Ministry of Food and Drug Safety to approve the test and will make it available as an in vitro diagnostic in the country by the end of 2016.
The deal includes unspecified milestone payments to Lophius from BL&H. Other financial details were not disclosed.